Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)
Date/Time: June 3, 2024; 3:00-6:00pm CDT
Location: Hall B1 & Livestream
Session:
Breast Cancer - Local/Regional/Adjuvant
Presenter: Kevin Kalinsky, MD, MS
|